A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy.
Phase of Trial: Phase III
Latest Information Update: 25 May 2016
At a glance
- Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 25 May 2016 Results published in the Epilepsia
- 10 Dec 2013 Results presented at the 67th Annual Meeting of the American Epilepsy Society.
- 28 Jul 2012 Planned number of patients changed from 100 to 125 as reported by European Clinical Trials Database.